Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: SOBI Announces U.S. Food And Drug Administration Approves Doptelet For The Treatment Of Thrombocytopenia In Pediatric Patients One Year And Older With Persistent Or Chronic Immune Thrombocytopenia

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    25/07/2025 12:02
    July 25 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:

SOBI ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION APPROVES DOPTELET® (AVATROMBOPAG) FOR THE TREATMENT OF THROMBOCYTOPENIA IN PEDIATRIC PATIENTS ONE YEAR AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

Source text: ID:nGNX100WjL

Further company coverage: SOBIV.ST

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news